Literature DB >> 2320592

Fibril in senile systemic amyloidosis is derived from normal transthyretin.

P Westermark1, K Sletten, B Johansson, G G Cornwell.   

Abstract

The amyloid fibril in senile systemic amyloidosis (SSA), like that of familial amyloidotic polyneuropathy, is derived from transthyretin (TTR). SSA, however, is a common disease, affecting to some degree 25% of the population greater than 80 years old. In familial amyloidotic polyneuropathy, the amyloidogenesis has been considered to depend on point mutations leading to TTR variants. We show that the TTR molecule in SSA, on the other hand, has a normal primary structure. Factors other than the primary structure of TTR must therefore be important in the pathogenesis of TTR-derived amyloid.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320592      PMCID: PMC53787          DOI: 10.1073/pnas.87.7.2843

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

2.  Cloning and sequence analysis of cDNA for human prealbumin.

Authors:  S Mita; S Maeda; K Shimada; S Araki
Journal:  Biochem Biophys Res Commun       Date:  1984-10-30       Impact factor: 3.575

3.  Revised analysis of amino acid replacement in a prealbumin variant (SKO-III) associated with familial amyloidotic polyneuropathy of Jewish origin.

Authors:  M Nakazato; K Kangawa; N Minamino; S Tawara; H Matsuo; S Araki
Journal:  Biochem Biophys Res Commun       Date:  1984-09-28       Impact factor: 3.575

4.  Senile cardiac amyloid: evidence that fibrils contain a protein immunologically related to prealbumin.

Authors:  G G Cornwell; P Westermark; J B Natvig; W Murdoch
Journal:  Immunology       Date:  1981-11       Impact factor: 7.397

5.  Substrate specificity of a proteolytic enzyme isolated from a mutant of Pseudomonas fragi.

Authors:  G R Drapeau
Journal:  J Biol Chem       Date:  1980-02-10       Impact factor: 5.157

6.  Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin.

Authors:  F E Dwulet; M D Benson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type).

Authors:  S Tawara; M Nakazato; K Kangawa; H Matsuo; S Araki
Journal:  Biochem Biophys Res Commun       Date:  1983-11-15       Impact factor: 3.575

8.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation.

Authors:  G G Cornwell; W L Murdoch; R A Kyle; P Westermark; P Pitkänen
Journal:  Am J Med       Date:  1983-10       Impact factor: 4.965

9.  Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin).

Authors:  M J Saraiva; S Birken; P P Costa; D S Goodman
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

10.  Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin.

Authors:  M Pras; F Prelli; E C Franklin; B Frangione
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

View more
  171 in total

Review 1.  Amyloidosis and the respiratory tract.

Authors:  J D Gillmore; P N Hawkins
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

Review 2.  The role of echocardiographic deformation imaging in hypertrophic myopathies.

Authors:  Maja Cikes; George R Sutherland; Lisa J Anderson; Bart H Bijnens
Journal:  Nat Rev Cardiol       Date:  2010-05-11       Impact factor: 32.419

3.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

4.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

5.  Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy.

Authors:  L H Connors; G Doros; F Sam; A Badiee; D C Seldin; M Skinner
Journal:  Amyloid       Date:  2011-06       Impact factor: 7.141

6.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

7.  Topological Analysis of Transthyretin Disassembly Mechanism: Surface-Induced Dissociation Reveals Hidden Reaction Pathways.

Authors:  Mehdi Shirzadeh; Christopher D Boone; Arthur Laganowsky; David H Russell
Journal:  Anal Chem       Date:  2019-01-28       Impact factor: 6.986

8.  Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.

Authors:  Maria Rosário Almeida; Bárbara Macedo; Isabel Cardoso; Isabel Alves; Gregorio Valencia; Gemma Arsequell; Antoni Planas; Maria João Saraiva
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

Review 9.  Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.

Authors:  Walid Hassan; Hani Al-Sergani; Walid Mourad; Rashed Tabbaa
Journal:  Tex Heart Inst J       Date:  2005

10.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.